ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for monitor 브라질 증권 거래소, NASDAQ, NYSE, AMEX, LSE 등 주요 거래소에서의 다양한 실시간 주식 시세를 모니터링합니다.
BriaCell Therapeutics Corporation

BriaCell Therapeutics Corporation (BCTX)

0.39
-0.0113
(-2.82%)
종가: 15 1월 6:00AM
0.3999
0.0099
( 2.54% )
시간외 거래: 7:25AM

개인 투자자를 위한 전문가급 도구.

주요 통계 및 세부정보

가격
0.3999
매수가
0.3901
매도가
0.427
거래량
414,484
0.38001 일간 변동폭 0.4024
0.38 52주 범위 4.61
market_cap
전일 종가
0.4013
개장가
0.40
최근 거래 시간
5
@
0.3901
마지막 거래 시간
07:25:31
재정 규모
US$ 161,943
VWAP
0.390711
평균 볼륨(3m)
1,507,225
발행 주식
35,838,161
배당수익률
-
주가수익률
-79.28
주당순이익(EPS)
-0.13
매출
-
순이익
-4.79M

BriaCell Therapeutics Corporation 정보

BriaCell Therapeutics Corp. is a clinical stage immuno-oncology company that is developing an entirely new class of targeted immunotherapies to transform cancer care. Bria-IMT(TM), BriaCell's lead candidate, was awarded Fast Track status by FDA and is being evaluated in a pivotal Phase 3 combination... BriaCell Therapeutics Corp. is a clinical stage immuno-oncology company that is developing an entirely new class of targeted immunotherapies to transform cancer care. Bria-IMT(TM), BriaCell's lead candidate, was awarded Fast Track status by FDA and is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC). MBC is breast cancer that has spread to other tissues. Bria-IMT(TM) is a targeted cell-based immunotherapy. Additionally, BriaCell is developing, Bria-OTS(TM), a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical study initially targeting breast cancer, with extension to prostate cancer, and other cancers. 더 보기

섹터
Aircraft
산업
Business Services, Nec
웹사이트
본부
Vancouver, British Columbia, Can
설립됨
2009
BriaCell Therapeutics Corporation is listed in the Aircraft sector of the 나스닥 with ticker BCTX. The last closing price for BriaCell Therapeutics was US$0.40. Over the last year, BriaCell Therapeutics shares have traded in a share price range of US$ 0.38 to US$ 4.61.

BriaCell Therapeutics currently has 35,838,161 shares in issue. The market capitalisation of BriaCell Therapeutics is US$14.38 million. BriaCell Therapeutics has a price to earnings ratio (PE ratio) of -79.28.

BCTX 최신 뉴스

BriaCell Announces Availability of Annual General Meeting Materials and Alternative Voting Procedures

PHILADELPHIA and VANCOUVER, British Columbia, Dec. 17, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage...

BriaPro Therapeutics Corp. Announces Availability of Annual General Meeting Materials and Alternative Voting Procedures

VANCOUVER, British Columbia, Dec. 17, 2024 (GLOBE NEWSWIRE) -- BriaPro Therapeutics Corp. (“BriaPro” or the “Company”), a pre-clinical stage immunotherapy company developing binding agents and...

BriaCell Therapeutics Announces Closing of $5.5 Million Public Offering

PHILADELPHIA and VANCOUVER, British Columbia, Dec. 13, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage...

BriaCell 2024 SABCS® Poster Highlights Ability of Bria-IMT™ Regimen to Increase Cancer-Fighting Immune Cells in Metastatic Breast Cancer

BriaCell reports influx of cancer fighting CD8+ “killer” T cell into metastatic breast cancer tumors and lymph organs turning “Cold” tumors and lymph nodes “Hot” on ImmunoPET imaging in cancer...

BriaCell Therapeutics Announces Pricing of $5.5 Million Public Offering

PHILADELPHIA and Vancouver, British Columbia, Dec. 11, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage...

BriaCell Therapeutics Announces Proposed Public Offering

PHILADELPHIA and VANCOUVER, British Columbia, Dec. 11, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage...

BriaCell Presents Unprecedented Overall Survival Data in Metastatic Breast Cancer in Spotlight Poster at 2024 SABCS®

Median overall survival (OS) to date of 13.4 months for Phase 2 patients treated with the Phase 3 formulation (15.6 months for those treated since 2022), double that of comparable patients in the...

BriaCell Receives Green-Light from Data Safety Monitoring Board for its Phase 3 Study in Metastatic Breast Cancer

The Data Safety Monitoring Board (DSMB) stated no safety concerns, and recommended continuation of BriaCell’s pivotal Phase 3 study of Bria-IMT™ plus an immune check point inhibitor in metastatic...

BriaCell 2024 SABCS® Spotlight Poster to Showcase Positive Overall Survival Data Across All Patient Subtypes in Metastatic Breast Cancer

SABCS® “Spotlight” poster to be presented on Wednesday, December 11, 2024 7:00 AM – 8:30 AM CST highlights positive BriaCell survival and clinical benefit data across all metastatic breast cancer...

BriaCell Provides Update to its Board of Directors

PHILADELPHIA, Pa. and VANCOUVER, British Columbia, Nov. 25, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage...

기간변동변동 %시가고가저가평균 일일 거래량VWAP
1-0.0781-16.33891213390.4780.4780.389478620.4256143CS
4-0.184531-31.574471580.5844310.66340.3811681450.52712509CS
12-0.4391-52.33611442190.8391.260.3815072250.7938471CS
26-0.5199-56.52315720810.91981.960.3831536680.72778108CS
52-3.9801-90.86986301374.384.610.3816433110.77557916CS
156-7.6001-95.00125812.090.387569192.54078441CS
260-3.8401-90.56839622644.2412.470.3811455414.48364573CS

BCTX - Frequently Asked Questions (FAQ)

What is the current BriaCell Therapeutics share price?
The current share price of BriaCell Therapeutics is US$ 0.3999
How many BriaCell Therapeutics shares are in issue?
BriaCell Therapeutics has 35,838,161 shares in issue
What is the market cap of BriaCell Therapeutics?
The market capitalisation of BriaCell Therapeutics is USD 14.38M
What is the 1 year trading range for BriaCell Therapeutics share price?
BriaCell Therapeutics has traded in the range of US$ 0.38 to US$ 4.61 during the past year
What is the PE ratio of BriaCell Therapeutics?
The price to earnings ratio of BriaCell Therapeutics is -79.28
What is the reporting currency for BriaCell Therapeutics?
BriaCell Therapeutics reports financial results in USD
What is the latest annual profit for BriaCell Therapeutics?
The latest annual profit of BriaCell Therapeutics is USD -4.79M
What is the registered address of BriaCell Therapeutics?
The registered address for BriaCell Therapeutics is SUITE 300 - 235 WEST 15TH STREET, VANCOUVER, BRITISH COLUMBIA, V7T 2X1
What is the BriaCell Therapeutics website address?
The website address for BriaCell Therapeutics is www.briacell.com
Which industry sector does BriaCell Therapeutics operate in?
BriaCell Therapeutics operates in the BUSINESS SERVICES, NEC sector

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
HSDTHelius Medical Technologies Inc
US$ 1.13
(63.29%)
3.27M
VMARVision Marine Technologies Inc
US$ 1.87
(33.57%)
9.03M
MASS908 Devices Inc
US$ 2.38
(20.20%)
710.42k
NIXXNixxy Inc
US$ 4.7599
(17.82%)
186
RPIDRapid Micro Biosystems Inc
US$ 1.25
(14.68%)
33.31k
CRKNCrown Electrokinetics Corporation
US$ 0.066
(-25.51%)
7.04M
RIMEAlgorhythm Holdings Inc
US$ 0.06195
(-20.78%)
12.24M
NMHINatures Miracle Holding Inc
US$ 1.32
(-13.73%)
1.13M
NCRANocera Inc
US$ 0.9299
(-13.09%)
75.42k
GIFTGiftify Inc
US$ 1.29
(-11.03%)
2.61k
BHATBlue Hat Interactive Entertainment Technology
US$ 0.0644
(4.04%)
12.53M
RIMEAlgorhythm Holdings Inc
US$ 0.06195
(-20.78%)
12.24M
RGTIRigetti Computing Inc
US$ 8.93
(-0.22%)
10.9M
VMARVision Marine Technologies Inc
US$ 1.8701
(33.58%)
9.03M
ERNAEterna Therapeutics Inc
US$ 0.4951
(8.10%)
7.2M

BCTX Discussion

게시물 보기
Monksdream Monksdream 1 주 전
BCTX, new 52 week low
👍️0
Invest-in-America Invest-in-America 1 월 전
BCTX: It's actually GREEN now in price!!! (Heck, maybe there IS a "God" --- of WOMEN, hopefully!!!! And NOT some clown nailed to a cross in Naples, Italy, 2K years ago!!!!)

👍️0
Invest-in-America Invest-in-America 1 월 전
BCTX: I sincerely HOPE that this BCTX stock --- with GREAT news for Women's BREAST Cancer concerns --- gets monster short-SQUEEZED, like below!!! Metaphorically speaking, that is.)

👍️0
shurtha2000 shurtha2000 1 월 전
Slow and Steady up
👍️0
Invest-in-America Invest-in-America 1 월 전
BCTX: The Markets simply do NOT give-a-fluck about WOMEN's issues of any sort!!! (BCTX could have PR'd that they have outright CURED all Breast Cancers, but this stock STILL would not have soared in price!!!)
👍️0
Invest-in-America Invest-in-America 1 월 전
BCTX: The only worrisome thing about anything (Medical) WOMEN's STUFF, is that they rarely if ever SOAR in price. (While mere FLUFF news about anything MEN's Medical issues --- like today's @CADL baloney PR -- often SOAR in price gloriously.)
👍️0
axelvento axelvento 1 월 전
Median overall survival (OS) to date of 13.4 months for Phase 2 patients treated with the Phase 3 formulation (15.6 months for those treated since 2022), double that of comparable patients in the literature
Final Phase 2 OS calculation is pending as many patients remain alive well over 1 year after starting the study
Median OS of 13.7 months in breast cancer patients with central nervous system (CNS) metastasis treated with the Bria-IMT™ regimen alone or in combination with an immune check point inhibitor (CPI)
Five BriaCell posters (four today and one on Dec 13 th ) showcase robust survival and clinical benefit data, plus key biomarker data from Phase 2 trial of Bria-IMT™ in metastatic breast cancer (MBC)
Biomarkers identify patients who benefit from treatments with the Bria-IMT™ regimen
No toxicity related discontinuations



https://feeds.issuerdirect.com/news-release.html?newsid=7743652450762128
👍️0
Invest-in-America Invest-in-America 1 월 전
BCTX: Much more IMPRESSIVE stats. for this BCTX news --- vs. the baloney stats. for @CADL's Prostate Cancer results, which were in truth mere STATISTICAL ARTIFACTS and, as such, significant of NOTHING!!
👍️0
TrendTrade2016 TrendTrade2016 1 월 전
BCTX OUT ON NEWS
👍️0
TrendTrade2016 TrendTrade2016 1 월 전
BCTX MASSIVE NEWS FOR THIS CANADIAN BIO
👍️0
TrendTrade2016 TrendTrade2016 1 월 전
BCTX BLOWING UP
👍️0
TrendTrade2016 TrendTrade2016 1 월 전
BCTX PUSHING TO TOP OF THE DAILY CLOUD VERY NICE
👍️0
glenn1919 glenn1919 2 월 전
BCTX..............................https://stockcharts.com/h-sc/ui?s=BCTX&p=W&b=5&g=0&id=p86431144783
👍️0
TrendTrade2016 TrendTrade2016 2 월 전
BCTX NICE CANADIAN BIO READY FOR A DOLLAR
👍️0
glenn1919 glenn1919 2 월 전
BCTX.........................https://stockcharts.com/h-sc/ui?s=BCTX&p=W&b=5&g=0&id=p86431144783
👍️0
axelvento axelvento 3 월 전
HUGE$ In BriaCell's Phase 2 clinical study, patients treated with the same Bria-IMT™ regimen formulation being used in the ongoing Phase 3 pivotal trial experienced a one-year survival rate of 55% (i.e. 55% of patients remain alive at least one year after starting on the study). This rate exceeds the survival data of the current standard of care for similar patients (see Table 1). Notably, 4 of 13 patients recruited in 2022 remain in survival follow-up as well, including:

Patient 01-009: Overall survival (OS) of 25 months has been reported in a patient who had failed 6 prior treatments prior to the BriaCell regimen. Stable disease and lymph node shrinkage has been recorded during 13 cycles of therapy.
Patient 07-001: OS of 24 months. She had stable disease and received 8 cycles of BriaCell's therapy.
Patient 16-003: OS of 15 months and received 8 cycles of therapy with stable disease. Prior to the BriaCell regimen, she had 7 lines of therapy, which included the progression of disease while on the antibody-drug conjugate (ADC) Enhertu.
Patient 11-018: OS of 14 months. This previously-reported responder with 100% resolution of her brain metastasis has recently completed her 19th cycle of therapy.
👍️ 1 ✌️ 1
stocktowatch stocktowatch 3 월 전
$BCTX No serious adverse events related to Bria-IMT™, 35 sites active and enrolling in pivotal Phase 3 study of Bria-IMT™, Pivotal Phase 3 study patient enrollment completion is expected in mid-2025

BIG NEWS https://feeds.issuerdirect.com/news-release.html?newsid=7546332967366263
👍 1
glenn1919 glenn1919 3 월 전
BCTX...........................https://stockcharts.com/h-sc/ui?s=BCTX&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 3 월 전
BCTX.........................https://stockcharts.com/h-sc/ui?s=BCTX&p=W&b=5&g=0&id=p86431144783
👍️0
Awl416 Awl416 3 월 전
BriaCell Reports 100% Resolution of Brain Metastasis in Breast Cancer Patient with “Eye-Bulging” Tumor
👍️0
1hot toddy 1hot toddy 3 월 전
wainwright issues buy on bctx with $15 price $$$$$$$$$$$ cure 4 breast cancer? and others
👍️0
1hot toddy 1hot toddy 4 월 전
Now the co has 8.5 mil for their business plan. Great for co. U got out and missed the push up as co has cure for breast cancer. Stock will rock
👍️0
glenn1919 glenn1919 4 월 전
BCTX........................................https://stockcharts.com/h-sc/ui?s=BCTX&p=W&b=5&g=0&id=p86431144783
👍️0
tw0122 tw0122 4 월 전
Gets out now millions of offering shares at .69…12,325,000 common shares. Each common share was sold at an offering price of $0.69 per share, for gross proceeds of approximately $8.5 million,
👎️ 1
glenn1919 glenn1919 4 월 전
BCTX..................................https://stockcharts.com/h-sc/ui?s=BCTX&p=W&b=5&g=0&id=p86431144783
👍️0
Awl416 Awl416 4 월 전
BriaCell Announces FDA-Authorized Expanded Access Policy for Metastatic Breast Cancer Patients
👍 1
boston127 boston127 4 월 전
Sorry. Wrong Board.
👍️0
Awl416 Awl416 4 월 전
BriaCell Therapeutics Announces $8.5 Million Offering
👍️0
PonkenPlonken PonkenPlonken 4 월 전
aks yourself why no BP wanted to be a part of this. Plenty of time to notice?
👍️0
glenn1919 glenn1919 4 월 전
BCTX..........................https://stockcharts.com/h-sc/ui?s=BCTX&p=W&b=5&g=0&id=p86431144783
👍️0
S3lfMade S3lfMade 4 월 전
I'm predicting an offering this week... Company needs cash. Under $1m currently
👍️0
subslover subslover 4 월 전
BriaCell Reports Positive Overall Survival (OS) in Metastatic Breast Cancer
Median overall survival of 15.6 months in Phase 2 Bria-IMT™ study patients treated in combination with immune checkpoint inhibitor
OS of 15.6 months compares favorably with 6.7-9.3 months reported for similar patients in the literature
Ongoing Phase 3 study investigating Bria-IMT™ in similar metastatic breast cancer population
No drug related discontinuations to date
PHILADELPHIA and VANCOUVER, British Columbia, Sept. 11, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce positive overall survival data of its Phase 2 clinical study of Bria-IMT™ in combination with an immune check point inhibitor (CPI) in late stage metastatic breast cancer.
https://www.otcmarkets.com/stock/BCTX/news/story?e&id=2978177
👍️0
Awl416 Awl416 4 월 전
Don’t blink
👍️0
Awl416 Awl416 4 월 전
BriaCell Reports Positive Overall Survival (OS) in Metastatic Breast Cancer
👍️0
dabonenose dabonenose 4 월 전
Good news and it goes lower again,,,lol
👍️0
Monksdream Monksdream 5 월 전
BCTX new 52 week low
👍️0
Monksdream Monksdream 6 월 전
BCTX new 52 week low
👍️0
Monksdream Monksdream 6 월 전
BCTX new 52 week low
👍️0
Monksdream Monksdream 6 월 전
BCTX under $2
👍️0
Monksdream Monksdream 7 월 전
BCTX new 52 week low
👍️0
Monksdream Monksdream 7 월 전
BCTX new 52 week low
👍️0
Monksdream Monksdream 9 월 전
BCTX. Under $3
👍️0
QuicKtip QuicKtip 9 월 전
$BCTX Shows “Strong Anti-Cancer Activity of Bria-OTS+™ and Bria-PROS+™ Clinical Candidates for Breast and Prostate Cancer”

Press Release: https://bit.ly/4aJmAoc

$BCTX #CancerTreatment #Innovation
👍️0
BigHeis BigHeis 10 월 전
Does anyone have information about the stock spinoff that occurred last year with this company? I have 600 shares of the spinoff security with 0 value and has remained that way since the spinoff. Thanks…
👍️0
Monksdream Monksdream 10 월 전
BCTX new 52 lo
👍️0
Monksdream Monksdream 10 월 전
BCTX new 52 lo
👍️0
Monksdream Monksdream 10 월 전
BCTX 10Q due March 13
👍️0
Monksdream Monksdream 11 월 전
BCTX new 52 week low
👍️0
Monksdream Monksdream 11 월 전
BCTX new 52 week low
👍️0
QuicKtip QuicKtip 1 년 전
$BCTX is thrilled to announce a new remarkable responder in our Phase 2 study of the Bria-IMT™ combination regimen. https://finance.yahoo.com/news/briacell-records-responder-remarkable-improvement-120000404.html
👍️0

최근 히스토리

Delayed Upgrade Clock